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Abstract 
Background: In the era of well-developed site-specific treatment strategies in cancer, identification of occult 
primary is of paramount importance in CUP patients. Furthermore, exact determination of the extent of the 
disease may help in optimizing treatment planning. The aim of the present study was to investigate additional 
value of F-18 FDG PET/CT in patients with cancer of unknown primary (CUP) as an appropriate imaging tool 
in early phase of initial standard work up. 
Materials and Methods: Sixty-two newly diagnosed CUP patients with inconclusive diagnostic CT scan of 
chest, abdomen and pelvis referring for F-18 FDG PET/CT were enrolled in this study. Standard of reference 
was defined as histopathology, other diagnostic procedures and a 3-month formal clinical follow up. The results 
of PET/CT were categorized as suggestion for primary site and additional metastasis and classified as true 
positive, false positive, false negative and true negative. The impact of additional metastasis revealed by F-18 
FDG PET/CT on treatment planning and the time contribution of F-18 FDG PET/CT in diagnostic pathway 
was investigated. 
Results: Sixty-two patients with mean age of 62 (30 men, 32 women), PET/CT correctly identified primary 
origin in 32% with false positive rate of 14.8%. No primary lesion was detected after negative PET/CT 
according to standard of reference. Sensitivity, Specificity and accuracy were 100%, 78% and 85%, 
respectively. Additional metastatic site was found in 56% with 22% impact on treatment planning. Time 
contribution for PET/CT was 10% of total diagnostic pathway. 
Conclusion: Providing higher detection rate of primary origin with excellent diagnostic performance, 
shortening the diagnostic pathway and improving treatment planning, F-18 FDG PET/CT may play a major 
role in diagnostic work up of CUP patients and may be recommended as an alternative imaging tool in early 
phase of investigation. 
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Cancer of unknown primary (CUP), which is defined 
as histopathologically-proven metastatic disease for 
which no primary site is detected despite through 
investigation, account for 3-5% of all diagnosed 
cancer cases1,2. Occult primary site may remain 
unidentified in up to 35-70% even at autopsy2,3. 
Diagnostic pathway of the CUP is quite variable4 and 
mostly time consuming with a yield of a slow as 30-
40%3,5. Therefore, early application of a highly 
sensitive and noninvasive diagnostic procedure early 
in initial standard work up of patient with CUP is of 
paramount importance. In addition to reveal the 
primary site, determining the best location for biopsy 
as well as the extent of the disease are other main 
issues should be addressed in CUP patients' work 
up6.  
Indeed, recognition a small subset of patients (20%) 
with a more favorable outcome who benefit from 
site-specific treatment strategies is the major role of 
imaging in CUP patients7,8. F-18 FDG PET/CT, as a 
whole body highly sensitive cross sectional imaging 
modality has gained a wide acceptance in oncology. 
Regarding the presumed hypothesis in biology of 
CUP, primary site may follow the parallel 
progression model which result in small sized 
primary lesion in the presence of metastasis 
development9.  
The advantage of PET/CT over the anatomical 
imaging is to reveal pathologic metabolic activity in 
normal sized structures.  In patients with CUP, 
primary site may be located anywhere through the 
body, furthermore, CUP often tends to follow 
unpredictable metastatic pattern10 and so whole body 
imaging modalities seem be the most useful 
diagnostic tools to achieve the highest diagnostic 
yield. In comparison with other whole body imaging, 
PET/CT has a less sophisticated interpretation.  
According to a large postmortem cohort studies11,12, 
the most common site of primary lesion include lung 
(27%), pancreas (24%), liver and bile duct (8%), 
kidney or adrenal glands (7%), colorectal (7%), 
genital system (7%) and stomach (6%). Recent 
professional guidelines in radiology, nuclear 
medicine as well as oncology highly recommend the 
use of F-18 FDG PET/CT in staging, restaging, 
treatment planning and response to treatment in most 
of the above-mentioned cancers13,14. Indeed, there is 
strong evidence indicating that patients with lung, 
hepato-pancreatic, genitourinary and colorectal cancer 
will benefit from the advanced diagnostic evaluation 
by F-18 FDG PET/CT, which results in improved 
management and outcome13,14. Therefore, it can be 
inferred that by any modality the occult primary lesion 
is detected, like the putative primary tumor, CUP 
patients may benefit from PET/CT assessment as a 
part of routine work up for staging, restaging and 
treatment planning as well as response to treatment.  
There is still debate in application of F-18 FDG 
PET/CT in CUP patients. No large-scale prospective 
study has yet validates the use of FDG PET/ in CUP. 
A recent meta-analysis including small retrospective 
studies demonstrates 37% increase in lesion detection 
rate by application of F-18 FDG PET/CT in 
comparison with conventional standard work up with a 
good sensitivity and specificity of as high as 84%15. 
Except for some particular scenario, the routine use of 
F-18 FDG PET/CT is not advocated in initial standard 
wok up of patent with CUP, especially early in 
diagnostic pathway.  
The present study evaluated retrospectively the 
diagnostic performance of F-18 FDG PET/CT in CUP 
patients in whom chest, abdominal and pelvic CT 
scan, as the cornerstone of imaging procedure in initial 
standard work up, fail to reveal the occult primary site, 
regardless the extent of the additional diagnostic work 
up. Furthermore, the contributory role of F-18 FDG 
PET/CT in shortening the diagnostic pathway is 
investigated. The aim of this study is to purpose the 
use of F-18 FDG PET/CT early in diagnostic 
evaluation of patient with CUP. 
Methods 
Patients: Seventy tow newly diagnosed CUP patients 
who were referred to PET/CT division of Masih 
Daneshvari Hospital (NRITLD) in Tehran, Iran, for 
advanced investigation by whole body PET/CT 
between May 2013 and May 2015 were enrolled in the 
study. All the patients with primary presentation of 
either biopsy-verified metastasis or related clinical 
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symptomsin whom standard initial work up including 
complete history and physical exam, full blood 
count, biochemistry as well as diagnostic contrast-
enhanced chest, abdominal and pelvic CT scan failed 
to identify the occult primary lesion or suggest the 
most appropriate site for biopsy were considered to 
be eligible. Regardless of the extend of baseline 
diagnostic work up, the main inclusion criterion 
considered necessary for eligibility was a negative 
full dose contrast-enhanced CT scan of chest, 
abdomen and pelvis.  
Exclusion criteria were met in 10 patients as the 
following: previous history of known malignancy 
(1), previous history of chemotherapy or radiation 
therapy (2), patients with lymphoma (2), incomplete 
medical records or follow-up (5) and diabetes 
mellitus (0). Finally, 62 patients registered as the 
cohort analyzed in current study. A stepwise 
approach was carried out for immunohistochemisry 
(IHC) assay of metastatic tissue diagnosis as the 
following: defining cell lineage by basic panel and 
then indentifying subtypes and predicting the site of 
origin, if possible. 
PET/CT acquisition protocol: Whole body F-18 
FDG PET/CT was performed by using an integrated 
PET/CT scanner (GE 690 Discovery, 64 Slice, Time 
Of Flight). Patients were fasted for at least 8 hours 
before injection. Blood glucose level was below 150 
mg/dl at the time of radiotracer injection. Sixty 
minutes after IV administration of 4.6MBq/Kg (0.13 
mCi/Kg) 18  F FDG image acquisition commenced 
craniocuadally with the CT component  performing 
by a multidetector CT scanner and the following 
parameters: auto mAs (50-120), 120 kV, noise factor 
19, 2.5 mm thickness.  Thirty minutes before 
imaging acquisition, 40cc meglumine 76% 
(containing 370mg Iodine /cc) in 1500 water was 
administered as oral contrast. The PET data were 
then collected in the reverse direction immediately 
after CT acquisition with time of 3 minutes per bed 
position. The PET raw data were corrected for 
attenuation, dead time, random and scatter 
coincidence, and subsequently reconstructed by 
iterative method and HD (high definition) technique. 
No premedication was administrated before injection. 
Interpretation criteria: A team comprised of 
experience radiologist and a nuclear medicine 
physician reviewed AC and NAC PET, CT and fused 
PET/CT images on advantage window 4.5, side-by 
side and reached in consensus for suggesting primary 
lesion and additional metastatic site. In current study 
positive case was considered as abnormal focal 
increased metabolic activity on PET images with 
inconclusive correspondence on CT images.  
Time contribution of F-18 FDG PET/CT 
The diagnostic pathway is defined as the time interval 
from the date of clinical manifestation or histological 
confirmation of metastasis to the end of the diagnostic 
pathway (whole course), i.e., the date of either biopsy 
verification of occult primary or the end of the 3-
month formal clinical follow-up. The time interval 
from F-18 FDG PET/CT study to the end of diagnostic 
course is subsequently extracted from the whole 
course (PET/CT course). The time contribution of F-
18 FDG PET/CT was represented as the following: 
(PET/CT course/whole course)×100. 
Standard of Reference: The vast majority of occult 
primary site remain unidentified even in postmortem 
study, hence a multidisciplinary approach was 
considered as the standard of reference. The 
suggestion for primary site was further correlated with 
the following standard of reference: (1) 
histopathology, (2) other imaging modalities with or 
without tissue diagnosis and (3) at least 3 months 
formal clinical follow up, including repeated physical 
examination and conventional diagnostic procedure 
(CT, US, mammography, endoscopy and MRI 
wherever indicated). Finally a conclusion was drawn 
by the oncologist based on all clinicoradipathologic 
evidences and classified the F-18 FDG PET/CT results 
as true positive, false positive, false negative and true 
negative.  
Data Analyses: By correlating the F-18 FDG PET/CT 
findings with standard of reference, the diagnostic 
performance of F-18 FDG PET/CT including 
sensitivity, specificity, and accuracy were calculated 
based on the standard formula as the following:  
Sensitivity: TP/(TP+FN), Specificity: TN/(TN+FP), 
and Accuracy: TP+TN/(TP+TN+FP+FN). 
Statistical analyses were conducted using SPSS 
version 18. Impact of additional metastatic sites 
revealed by PET/CT on treatment planning was 
evaluated as change the therapeutic strategy from local 
to systemic. 
Results 
Demographic characteristics: Sixty-two patients (30 
men: 48.4%, 32 women: 51.6%), with mean age of 62 
years (range: 31-82 years) were enrolled in the study. 
In addition to a negative contrast-enhanced diagnostic 
chest, abdominal and pelvic CT scan, all the patients 
had inconclusive conventional diagnostic work up, 
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including ultrasound examination, endoscopic 
procedure, MRI/MRM and bone scan. The detailed 
base line examinations are summarized in Table 1.  
Except for 8 patients presented with relevant clinical 
symptom (13.1%), at least one biopsy-proven 
metastatic site was indentified in 54 patients (68.9%). 
The distribution of the most common sites of 
metastasis was in order as the following: bone 
(11/54, 20.4%), extra-cervical adenopathies (10/54, 
18.6%), liver and lung (8/54: 14.8%). The most 
frequent histopathologic findings in metastatic 
location was adenocarcinoma (29/54; 53.8%) 
followed by poorly differentiated adenocarcinoma 
(9/54; 16.6%), squamous cell carcinoma and small 
cell undifferentiated cancer (5/54; 9.3%). An 
overview of location and histopathology of 
metastatic site are provided in Table 2. 
PET/CT suggestion for primary origin: 62 patients, 
PET/CT suggested primary site in 29 cases (48.8%), 
20 of which were subsequently proved to be correct by 
histopathologic confirmative examination as the 
standard of reference (true positive rate; 32.3%), 
mainly in the following locations: lung (13/20, 65%), 
pancrease and hepatobiliary (2/20, 10%) and 
colorecatal and nasopharynx (1/20, 5%).  True positive 
findings mostly occurred in patients presented with 
liver (6/20, 30%), extracervical lymph node (5/20, 
25%) and bone (4/20, 20%) metastasis. Findings for 
other 9 cases were categorized as false positive since 
no evidence of cancer tissue was identified in 
histopathologic study (false positive rate: 14.5%). 
False positive findings were recognized in lung (5/9, 
55.5%), breast and colorectal (2/9. 22.2%). An 
overview of PET/CT findings are provided in Table 3. 
Table 1: Baseline Examination other than Diagnostic 
CT scan of chest, abdomen and pelvis. 
% of Total  No. of patient Baseline Examination 
33.8% 21 Ultrasound Exam 
16.1% 10 Bone Scan 
9.7% 6 Colonoscopy 
8.1% 5 Endoscopy 
6.5% 4 MR mammography 
1.6% 1 Chest X-ray 
3.2% 2 Mammography 
1.6% 1 Larygoscopy 
11.3% 7 Ultrasound Exam + Bone Scan 
8.1% 5 Ultrasound Exam + Endoscopy 
3.2% 2 Ultrasound Exam + Endoscopy + Bone Scan 
1.6% 1 
Ultrasound Exam + 
Endoscopy + 
Mammography 
1.6% 1 Exclusively Bone Scan 
1.6% 1 Exclusively MRM 
 
 






  Location of Metastasis 
20.4 11 Bone  
18.6 10 Extracervical lymphadenopathy 
14.8 8 Lung  
14.8 8 Liver  
9.3 5 Brain  
3.7 2 Peritoneum 
7.4 4 Others  
  Histopathology  
53.8 29 Adenocarcinoma 
16.6 9 Poorly differentiated Adenocarcinoma 





3.7 2 Neuroendocrine  













Total Patients PET-Positive Patients
 
 





Figure 2. A 58-year old man with metastatic adenocarcima of 
liver. Chest, abdominal and pelvic CT scan failed to identify the 
site of origin. The occult primary in pancreas was suggested only 
on PET and fused PET/CT images which were subsequently 
proven by histopathologic confirmative study. 
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Of 33 PET/CT-negative patients, no primary lesion 
were identified by other diagnostic procedures and 
formal clinical follow up, results in false negative 
rate of 0 and true negative rate of 53.2%.  Sensitivity, 
specificity and accuracy were calculated as 100%, 
78% and 85%, respectively. In patients presented 
with clinical symptoms, PET/CT failed to identify 
any primary lesion correctly, however, false positive 
rate was 4 out of 8 (6.4% of total patients). 
PET/CT detection rate for additional metastasis: 
PET/CT revealed additional metastasis in 56.4% 
(35/62) which results in change in treatment planning 
in 22% (13/62). The most frequent sites of additional 
metastasis detected by PET/CT were mediastinal, 
hilar, retroperitoneal lymph nodes and adrenal gland. 
PET/CT revealed additional metastatic sites in 11 out 
of 33 patients in whom PET/CT failed to suggest 
primary origin (33.3%). These findings resulted in 
change in treatment planning in 7 cases (13.5% of 
total patients). 
Time contribution of PET/CT in diagnostic 
pathway: The mean total diagnostic pathway and 
time interval between PET/CT to end of the study 
were demonstrated as 264 days (range of 88-585 
days) and 27 days (range 15-80 days), respectively. 
PET/CT contributed only the terminal10% of the 
total diagnostic course (Figure 1). This ratio was 
calculated as 9.8% in patient with true positive 
suggestion of primary origin on PET images (Figure 
2). 
Discussion 
Debates still present on the role of F-18 FDG 
PET/CT in CUP patients. According to the last 
updated practical guidelines of NCCN in April 2013, 
the application of F-18 FDG PET/CT in CUP 
patients is confined to the detection of primary tumor 
in patients presenting with cervical metastatic 
adenopathies of squamous cell origin with a higher 
detection rate of 25-50% in comparison with contrast-
enhanced CT or CT/MRI16, 17 as well as performing 
additional information about the extent of disease 
which may help in optimizing treatment planning, 
particularly field of radiotherapy18.  
Except for some clinical scenario, the routine use of F-
18 FDG PET/CT is not yet advocated in CUP patients. 
It seems that the lack of homogenous cohort large-
scale prospective studies validating the use of F-18 
FDG PET/CT in CUP patients has been impeded the 
wide application of this imaging modality as a part of 
standard work in CUP. Demonstrating 37% more 
detection rate of primary origin with an acceptable 
sensitivity and specificity (84%), the results of a recent 
meta-analysis and systematic reviews are promising 
for F-18 FDG PET/CT application in CUP16 which is 
compatible with the results of present study; however, 
some other investigations considered no superiority for 
F-18 FDG PET/CT over conventional diagnostic work 
up in either detection of primary lesion or impact on 
patient’s management in CUP19,20.  
Moderate-quality methodologies such as small sample 
size19 as well as methodological differences including 
various interpretation criteria and standard of reference 
may have great influence on the results. Furthermore, 
the wide variety of patients' characteristics such as 
various sites of metastatic presentation and the extent 
of baseline examinations may negatively influence the 
validity of results.  
A recent study which prospectively compared the 
diagnostic performance of F-18 FDG PET/CT with 
full dose contrast-enhanced CT have demonstrated no 
statically significant difference in detection rate of 
Table 3: Overview of PET/CT primary suggestion. 
 Location 
 Lung Pancreas Hepatobiliary Colorectal Nasopharynx Muscle Breast Total 
 no % no % no % no % no % no % no % no % 
True 
Positive 
13 65 2 10 2 10 1 5 1 5 1 5   20 32.3 
False 
Positive 
5 55.5     2 22.2     2 22.2 9 14.5 
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primary lesion (28.1% vs.31.9%) as well as 
sensitivity (57.6 vs. 65.2), specificity (71 vs. 60.9) 
and accuracy (64.4 vs. 63) between these two 
modalities21. In the mentioned study, hyper-
metabolic lesion on PET images with no apparent 
correspondence on CT images was considered as 
negative, however, there are strong evidences 
indicating that malignant metabolic changes, which 
can be easily identified by F-18 FDG PET/CT, 
frequently occur in very small sized or even normal 
sized structures in CUP22,23 resulting in missing the 
small sized primary lesions in the presence of such 
interpretation criteria. Hence, the diagnostic 
performance of F-18 FDG PET/CT may be 
underestimated in the mentioned study. Considering 
interpretation criteria on the basis of abnormal 
metabolic activities corresponding with in 
determinate CT findings, the current study attributed 
32.3% more detection ratetoF-18 FDG PET/CT. This 
may represent the diagnostic power of F-18 FDG 
PET/CT more accurately. 
Some reports have claimed that in the presence of 
complete diagnostic work up, PET/CT may not show 
any significant additional benefits in either detection 
of occult primary or in the patient’s management and 
hence, the additional value of FDG PE/CT in CUP 
patients may be overestimated24. However, 
identification of primary origin is not the only issue 
should be addressed in CUP patients. Determination 
of the extent of the disease not only is helpful in 
recognition of the small population of CUP patients 
with favorable outcome6,25 but also may help in 
optimizing treatment planning including field of 
radiation therapy and also evaluation of response to 
treatment25. In the current study, PET/CT detected 
additional metastatic site in56.4% which results in 
22% change in treatment planning. This result is in 
line with some other reports demonstrating 27% 
additional metastasis revealed by PET/CT22.  
No standard and harmonized diagnostic algorithm is 
currently accepted for initial work up of CUP 
patients. According to the literatures, CUPs do not 
behave exactly the same as putative known primary 
tumor including the pattern of metastatic spread10. 
Hence, the focused stepwise diagnostic approach, as 
the most advocated diagnostic work up in CUP, may 
encounter a great challenge. On the other hand, 
despite extensive diagnostic work up, primary tumor 
detection yield is generally low, even on postmortem 
studies. In addition, nonselective exhaustive tests are 
usually time consuming and rarely result in improved 
diagnostic yield2,3.False negative rate is greatly 
influenced by the various interpretation criteria and 
standard of reference; however, recent studies 
demonstrated that after a negative PET study, the 
probability of developing a primary tumor in CUP 
with a cervical metastatic presentation is extremely 
low(5/60, 5.3% with a mean follow-up period of 31.1 
months and 1/17, 5.8% with a mean follow-up period 
of 31.1 months)22,26. Though not conclusive because of 
short follow-up period, this is in line with the results 
of current study which demonstrated that no primary 
origin was detected after a negative PET/CT during a 
3-month clinical follow- up. Accordingly, application 
of PET/CT as a highly sensitive whole body imaging 
modality may be advisable in early phase of diagnostic 
pathway.  
There are growing evidences indicating that F-18 FDG 
PET/CT has a major role in management of patients 
with lung, pancreas, hepatobiliary and colorectal 
cancer13, 14 which are demonstrated as the most 
common primary sites in CUP11. The most frequently 
sites of primary lesion detected by PET/CT are lung 
(33%), oropharynx (16%), pancreas (4.8%) and breast 
(4.3%)15 which are in line with the results of the 
present study. Currently, it is believed that occult 
primary site may still retain some characteristics of 
putative known primary tumors26, so by any diagnostic 
modality the primary origin is picked up, CUP patients 
may benefit from complementary evaluation by 
PET/CT scan for staging, treatment planning and 
evaluation of treatment response8. 
It is of paramount importance to note that CUP is 
inherently a heterogeneous group of metastatic cancer 
and no common biologic behavior could be 
attributable to this entity26. Furthermore, it has been 
shown that CUPs do not confirm the similar behavior 
as the putative known tumor even in the pattern of 
metastatic spread10. Therefore, researches on CUP 
should be carried out on homogenous cohorts. Recent 
studies have indicated that F-18 FDG PET/CT 
diagnostic performance may vary depending on the 
location of the firs metastatic presentation. One study 
demonstrated that detection rate of primary tumor in 
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patients who present with lung and peripheral lymph 
node metastasis is considerably higher than those 
who present with liver, brain and other sites of 
metastasis. Detection rate for the patients who 
present with bone metastasis do not show statically 
significant difference between CT and FDG PET in 
this study27. Conversely, another study has been 
shown that PET/CT is more helpful in CUP patients 
with primary presentation of bone metastasis28. In the 
present study, primary lesion detection mostly 
occurred in patients presented with liver, 
extracervical lymph node and bone metastasis, 
however the results may greatly influenced by the 
distribution pattern of metastatic locations in this 
study which occurred mainly in  bone, extracevical 
lymph nodes and liver. Though not conclusive, the 
highest rate of false positivity occurred in patients 
who were referred for PET/CT evaluation based on 
relevant clinical symptom. Regarding the fact that 
sample size of CUP subclasses in considerably low, 
validation of the results requires more large-scaled 
studies. 
In the present study, the time contribution of F-18 
FDG PET/CT was the terminal 10.23% of total time 
of diagnostic pathway. It can be inferred that 
application of F-18 FDG PET/CT in early phase of 
initial work up may be considered as a time-saving 
approach results in reaching at the endpoint of the 
investigation earlier. However, the impact on 
prognostic outcome is not investigated in current 
study.   
Some limitations are encountered in the present 
study. Unavailability of postmortem investigation as 
well as short follow-up period may negatively effect 
on the accuracy of true-negative rate and hence the 
sensitivity. Furthermore, not all the additional 
metastatic sites were confirmed histopathologically. 
The definite value of PET/CT application in early 
phase of diagnostic pathway require a prospective 
randomized clinical trial with 2 arms evaluatingthe 
impact of early versus late PET/CT investigation in 
CUP patients. Small sample size restricted the 
validation of the result in different subclasses of CUP 
patient. Other potential drawback can be summarized 
as below: retrospective nature of the study, relatively 
small sample size as well as heterogeneity of patients' 
population. 
Conclusion 
Providing higher detection rate of primary origin with 
excellent diagnostic performance and improving 
treatment planning as well as shortening the diagnostic 
pathway, F-18 FDG PET/CT may play a major role in 
diagnostic work up of patients with CUP and may be 
recommended as an alternative imaging tool in early 
phase of investigation. 
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